 |
Hikma in bid for Boehringer's generics unitJordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr More… |
|
Hikma in bid for Boehringer's generics unitJordan's Hikma Pharmaceuticals has emerged as a bidder for German drugmaker Boehringer Ingelheim's generics unit Roxane Labs, Bloomberg reported, citing people familiar with the matter. Other bidders for the US-based Boehr More… |
 |
University of Sharjah team wins Think Science awardsA University of Sharjah-College of Pharmacy student, partly sponsored by leading pharmaceutical company Boehringer Ingelheim, has won two awards at the annual Think Science Competition, which is organised by Emirates Foundation for Youth Develop More… |
 |
Boehringer unveils inhibitor treatment for type 2 diabetesBoehringer Ingelheim, a leading pharmaceutical company, has unveiled the new DDP-4 inhibitor treatment for those with type 2 diabetes, which is the most common form of diabetes often leading to chronic complications like cardiovascular, kidney a More… |
 |
Boehringer’s Mena growth tops 14pc in H1Germany-based Boehringer Ingelheim, a top research-driven pharmaceutical company, has recorded a sales growth of 14.3 per cent during the first half of the year in the Mena region. Net global sales rose by 3.1 per cent, currency-a More… |
 |
Boehringer, Eli Lilly in major diabetes drugs dealBoehringer Ingelheim and Eli Lilly and Company today announced a global agreement to jointly develop and commercialise a portfolio of diabetes compounds currently in mid- and late-stage development. Included are Boehringer Ingelheim’s two More… |
